These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9020492)

  • 1. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
    de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
    Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ; Norman AR; Dearnaley DP; Horwich A
    J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
    Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
    Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
    Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
    Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
    Price P; Hogan SJ; Bliss JM; Horwich A
    Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
    Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
    de Wit R; Collette L; Sylvester R; de Mulder PH; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Stoter G
    Br J Cancer; 1998 Nov; 78(10):1350-5. PubMed ID: 9823978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
    Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
    Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumour marker regression rate following chemotherapy for malignant teratoma.
    Horwich A; Peckham MJ
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1463-70. PubMed ID: 6209145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis following chemotherapy for metastatic malignant teratoma.
    Horwich A; Easton D; Husband J; Nicholas D; Peckham MJ
    Br J Urol; 1987 Jun; 59(6):578-83. PubMed ID: 2446691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
    Vogelzang NJ; Lange PH; Goldman A; Vessela RH; Fraley EE; Kennedy BJ
    Cancer Res; 1982 Nov; 42(11):4855-61. PubMed ID: 6181870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pattern of gamma-glutamyl transpeptidase, alkaline phosphatase, serum glutamyl oxalate transaminase and serum glutamyl pyruvate transaminase in patients with disseminated non-seminomatous testicular tumors.
    van 't Sant P; Sleijfer DT; Schraffordt Koops H; Suurmeijer AJ; Willemse PH; De Bruijn HW; Marrink J; Ockhuizen T
    Eur J Cancer Clin Oncol; 1984 Feb; 20(2):209-15. PubMed ID: 6200328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours.
    Horwich A; Brada M; Nicholls J; Jay G; Hendry WF; Dearnaley D; Peckham MJ
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):177-84. PubMed ID: 2467806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
    Bosl GJ; Head MD
    Int J Biol Markers; 1994; 9(1):25-8. PubMed ID: 7519650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
    Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
    Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
    Seckl MJ; Rustin GJ; Bagshawe KD
    Br J Cancer; 1990 Jun; 61(6):916-8. PubMed ID: 1695522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
    Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
    Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early changes in serum alpha-fetoprotein after chemotherapy in advanced testicular tumors].
    Yamazaki H; Kondo N; Imanaka K; Kuroda A; Nakauchi K; Machida T
    Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1010-6. PubMed ID: 1699019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.